查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1370883

氣喘治療市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按藥物類別、管理模式、配銷通路、地區和競爭細分

Asthma Treatment Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Class, By Mode of Administration, By Distribution Channel, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球氣喘治療市場在 2024-2028 年預測期內將出現令人印象深刻的成長。這可以歸因於氣喘盛行率的增加、研發活動的增加以及醫療基礎設施投資的增加。氣喘是許多國家的主要公共衛生問題之一，特別是在美國。此疾病的高負擔產生了對有效氣喘治療的強烈需求。這導致了對開發可以預防氣喘感染或減輕其嚴重程度的藥物的大量投資。世界衛生組織 (WHO) 估計，氣喘影響全球約 2.35 億人，每年導致約 383,000 人死亡。

生物藥物，也稱為免疫調節劑，是一類針對參與免疫反應的特定分子的新型藥物。用於氣喘的生物藥物的例子包括奧馬珠單抗、美泊利珠單抗和貝那利珠單抗。這些藥物可降低嚴重且不受控制的氣喘患者氣喘發作的頻率和嚴重程度。人們對使用行動應用程式和穿戴式裝置等數位健康技術來治療氣喘越來越感興趣。這些工具可以幫助患者監測他們的症狀，追蹤他們的藥物使用情況，並獲得個人化的治療建議。

政府和私人機構經常進行公眾宣傳活動，教育人們了解氣喘的原因、症狀和治療方法。這些活動包括社交媒體活動、電視和廣播廣告以及宣傳冊和小冊子等教育材料。這提高了人們的認知，並導致全球氣喘治療市場的成長。

市場概況
預測期 2024-2028
2022 年市場規模 240.1億美元
2028 年市場規模 323.1億美元
2023-2028 年年複合成長率 5.09%
成長最快的細分市場 吸入器
最大的市場 北美洲

私營機構可以參與宣傳和遊說工作，以促進支持氣喘治療和管理的政策和措施。這可以包括努力提高氣喘藥物的保險覆蓋範圍，增加氣喘研究的資金，以及促進清潔空氣計劃以減少氣喘誘因。隨著私人機構讓人們意識到這會增加全球氣喘市場。

哮喘盛行率增加

氣喘盛行率的不斷上升是全球氣喘治療市場的主要驅動力之一。氣喘是一種由遺傳和環境因素共同引起的慢性呼吸道疾病，透過遺傳、環境因素、呼吸道感染、肥胖和壓力傳播給人類。 《2018 年全球氣喘報告》預測，氣喘將繼續成為全球重大健康問題，低收入和中等收入國家的負擔日益增加。報告指出，如果預防、診斷和治療方面沒有顯著改善，到2030年，與氣喘相關的死亡人數可能會增加20%。氣喘盛行率的不斷上升導致公眾對該疾病的認知不斷提高。這有助於減少對該疾病的恥辱感，並促進人們更好地了解有效治療和管理的必要性。根據《2018 年全球氣喘報告》，估計 2016 年全球有 3.39 億人受到氣喘影響。隨著氣喘盛行率的增加，越來越需要醫療基礎設施來支持疾病的診斷和治療。這可能會導致對醫療保健系統的投資增加，包括開發新的診所、醫院和其他醫療保健設施。世界衛生組織 (WHO) 報告稱，近年來，全球公眾對氣喘的認知有所提高，這有助於減少對該疾病的恥辱感，並促進更好地了解有效治療和管理的必要性。

提供醫療保健服務

提供醫療保健對於促進全球氣喘治療市場至關重要。氣喘是一種慢性疾病，需要持續的管理和治療，包括定期監測、藥物和後續護理。無法獲得醫療保健的氣喘患者可能無法接受適當的治療，這可能導致嚴重的併發症，例如住院、急診室就診，甚至死亡。根據《2018 年全球氣喘報告》，2016 年氣喘估計導致全球 461,000 人死亡。

獲得醫療保健可以透過多種方式促進全球氣喘治療市場。首先，它可以幫助早期識別氣喘患者，以便及時診斷和治療。這可以防止更嚴重的氣喘症狀並減少緊急護理的需要。此外，醫療保健提供者可以為氣喘患者提供教育和支持，幫助他們了解自己的病情並有效管理症狀。在美國，估計約有 2500 萬人患有氣喘，其中許多人由於獲得醫療保健和定期監測呼吸系統健康而在兒童時期被診斷出。

獲得醫療保健可以確保氣喘患者能夠獲得適當的藥物和治療選擇。這可以包括控制症狀的短期藥物以及預防氣喘發作的長期藥物。獲得醫療保健可以為氣喘患者提供接觸過敏症專家或肺科醫生等專家的機會，他們可以提供更專業的護理和治療。預計全球氣喘治療市場的成長。

增加研發投入

製藥公司正在大力投資研發，以開發新的創新氣喘治療方法。氣喘是一種複雜的疾病，需要持續的管理和治療，並且需要新的和改進的治療方法來解決未滿足的醫療需求。美國國立衛生研究院 (NIH) 每年為氣喘研究提供超過 1 億美元的資金，支持新療法、疾病機制和預防策略的研究。它可以幫助確定氣喘的新藥物標靶和治療方案。這可能包括開發新藥、生物製劑或合併療法，為氣喘患者提供更有效、更有針對性的治療選擇。

研發投資有助於提高對氣喘潛在機制的了解，並確定用於診斷和監測的新生物標記。這可以實現更個人化的治療方法，從而帶來更好的結果並降低醫療成本。研發投資有助於改善氣喘管理和教育，從而更好地自我管理疾病並減少醫療保健利用率。它可以包括開發用於監測和管理氣喘症狀的新設備和技術，以及針對醫療保健提供者和患者的教育計劃。

市場區隔

全球氣喘治療市場可按藥物類別、給藥方式、配銷通路和地區進行細分。依藥物類別，全球氣喘治療市場可分為短效BETA受體激動劑（SABA）、長效BETA受體激動劑（LABA）、吸入性皮質類固醇（ICS）、白三烯調節劑、免疫調節劑、聯合用藥等。根據給藥方式，全球氣喘治療市場分為吸入器、霧化器和口服藥物。根據配銷通路，全球氣喘治療市場分為醫院藥局、零售藥局、網路藥局等。從地區來看，全球氣喘治療市場可分為北美、歐洲、亞太地區、南美洲、中東和非洲。

市場參與者

GlaxoSmithKline, Plc.、AstraZeneca Plc、Teva Pharmaceutical Industries Ltd、Boehringer Ingelheim Gmbh、Merck & Co. Inc.、Novartis AG、Sanofi SA、Roche Holding AG、Regeneron Pharmaceutical Inc、Pfizer Inc. 是全球營運的一些領先企業氣喘治療市場。

報告範圍：

在本報告中，除了以下詳細介紹的產業趨勢外，全球氣喘治療市場也分為以下幾類：

氣喘治療市場，依藥物類型：

  • 短效 BETA 激動劑 (SABA)
  • 長效 BETA 受體激動劑 (LABA)
  • 吸入性皮質類固醇 (ICS)
  • 白三烯調節劑
  • 免疫調節劑
  • 複方藥物
  • 其他

氣喘治療市場，依管理模式分類：

  • 吸入器
  • 霧化器
  • 口服藥物
  • 氣喘治療市場，按配銷通路
  • 醫院藥房
  • 零售藥局
  • 網路藥局
  • 其他

氣喘治療市場，按地區：

  • 北美洲
  • 美國
  • 加拿大
  • 墨西哥
  • 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 亞太地區
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 中國
  • 南美洲
  • 巴西
  • 哥倫比亞
  • 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

競爭格局

  • 公司簡介：全球氣喘治療市場主要公司的詳細分析。

可用的客製化：

  • 根據給定的市場資料，TechSci Research 可根據公司的具體需求提供客製化服務。該報告可以使用以下自訂選項：

公司資訊

  • 其他市場參與者（最多五個）的詳細分析和概況分析。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球氣喘治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類別（短效 BETA 受體激動劑 (SABA)、長效 BETA 受體激動劑 (LABA)、吸入性皮質類固醇 (ICS)、白三烯調節劑、免疫調節劑、組合藥物、其他）
    • 依給藥方式（吸入器、霧化器、口服藥物）
    • 按配銷通路（醫院藥房、零售藥房、網路藥房、其他）
    • 按地區
    • 按公司分類 (2022)
  • 產品圖
    • 按藥物類別
    • 按管理方式
    • 按配銷通路

第 6 章：北美氣喘治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按管理方式
    • 按配銷通路
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲氣喘治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按管理方式
    • 按配銷通路
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太地區氣喘治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按管理方式
    • 按配銷通路
    • 按國家/地區
  • 亞太地區：國家分析
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲氣喘治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按管理方式
    • 按配銷通路
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲氣喘治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按管理方式
    • 按配銷通路
    • 按國家/地區
  • MEA：國家分析
    • 南非氣喘治療
    • 沙烏地阿拉伯氣喘治療
    • 阿拉伯聯合大公國氣喘治療

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 併購
  • 產品發布

第 13 章：全球氣喘治療市場：SWOT 分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第15章：競爭格局

  • 商業概覽
  • 產品供應
  • 最近的發展
  • 主要人員
  • SWOT分析
    • GlaxoSmithKline, Plc.
    • AstraZeneca Plc
    • Teva Pharmaceutical Industries Ltd
    • Boehringer Ingelheim Gmbh
    • Merck & Co. Inc
    • Novartis AG
    • Sanofi SA
    • Roche Holding AG
    • Regeneron Pharmaceutical Inc
    • Pfizer Inc.

第 16 章：策略建議

簡介目錄
Product Code: 15533

Global asthma treatment market will witness an impressive growth during the forecast period, 2024-2028. This can be ascribed to the increasing prevalence of asthma, growing R&D activities and increasing investment in healthcare infrastructure. Asthma is one of the major public health problem in many countries, particularly in the United States. The high burden of the disease has created a strong demand for effective Asthma Treatment. This has led to significant investment in the development of medications that can prevent Asthma Infection or reduce its severity. The World Health Organization (WHO) estimates that asthma affects around 235 million people worldwide and is responsible for approximately 383,000 deaths annually.

Biologic medications, also known as immunomodulators, are a new class of drugs that target specific molecules involved in the immune response. Examples of biologic medications used for asthma include omalizumab, mepolizumab, and benralizumab. These medications reduce the frequency and severity of asthma exacerbations in patients with severe, uncontrolled asthma. There is growing interest in the use of digital health technologies, such as mobile apps and wearable devices, for the management of asthma. These tools may help patients to monitor their symptoms, track their medication use, and receive personalized treatment recommendations.

Governments and private agencies often run public awareness campaigns to educate people about the causes, symptoms, and treatment of asthma. These campaigns include social media campaigns, television and radio ads, and educational materials such as brochures and pamphlets. This increases awareness among people and results in the growth of global asthma treatment market.

Market Overview
Forecast Period2024-2028
Market Size 2022USD24.01 Billion
Market Size 2028USD32.31 Billion
CAGR 2023-20285.09%
Fastest Growing SegmentInhalers
Largest MarketNorth America

Private agencies may engage in advocacy and lobbying efforts to promote policies and initiatives that support asthma treatment and management. This can include efforts to improve insurance coverage for asthma medications, increase funding for asthma research, and promote clean air initiatives to reduce asthma triggers. As the private agencies make people aware this increases the global asthma market.

Increasing Prevalence of Asthma

The growing prevalence of asthma is one of the key drivers of the global asthma treatment market. Asthma is a chronic respiratory condition that is caused by a combination of genetic and environmental factors, which is transmitted to humans through genetics, environmental factors, respiratory infection, obesity, and stress. Global Asthma Report 2018 predicts that asthma will continue to be a significant global health concern, with an increasing burden in low- and middle-income countries. The report notes that without significant improvements in prevention, diagnosis, and treatment, the number of asthma-related deaths may increase by 20% by 2030. The growing prevalence of asthma has led to increased public awareness of the condition. This has helped to reduce stigma around the condition and promote better understanding of the need for effective treatment and management. According to Global Asthma Report 2018, an estimated 339 million people worldwide were affected by asthma in 2016. As the prevalence of asthma increases, there is a greater need for healthcare infrastructure to support the diagnosis and treatment of the condition. This can lead to increased investment in healthcare systems, including the development of new clinics, hospitals, and other healthcare facilities. The World Health Organization (WHO) reports that there has been an increase in public awareness about asthma globally in recent years, which has helped to reduce stigma around the condition and promote better understanding of the need for effective treatment and management.

The growing prevalence of asthma drives research and development in the field of asthma treatment. As more people are diagnosed with asthma, there is a greater need for new and more effective treatments to manage the condition.

Providing Access to Healthcare

Providing access to healthcare is essential for promoting the global asthma treatment market. Asthma is a chronic condition that requires ongoing management and treatment, including regular monitoring, medication, and follow-up care. People with asthma who do not have access to healthcare may not receive appropriate treatment, which can lead to serious complications, such as hospitalization, emergency room visits, and even death. According to the Global Asthma Report 2018, asthma is estimated to have caused 461,000 deaths globally in 2016.

Access to healthcare can promote the global asthma treatment market in several ways. Firstly, it can help to identify people with asthma early, allowing for prompt diagnosis and treatment. This can prevent the development of more severe asthma symptoms and reduce the need for emergency care. Additionally, healthcare providers can provide education and support people with asthma, helping them to understand their condition and manage their symptoms effectively. In the United States, it is estimated that around 25 million people have asthma, and many of these are diagnosed in childhood due to access to healthcare and regular monitoring of respiratory health.

Access to healthcare can ensure that people with asthma have access to appropriate medications and treatment options. This can include both short-term medications to manage symptoms as well as long-term medications to prevent asthma attacks from occurring. Access to healthcare can provide people with asthma with the access to specialists, such as allergists or pulmonologists, who can provide more specialized care and treatment. anticipated in the growth of global asthma treatment market.

Increasing Investment in Research and Development

Pharmaceutical companies are investing heavily in research and development to develop new and innovative asthma treatments. Asthma is a complex disease that requires ongoing management and treatment, and there is a need for new and improved treatments to address unmet medical needs. The National Institutes of Health (NIH) in the United States provides over USD 100 million in funding for asthma research each year, supporting research into new treatments, disease mechanisms, and prevention strategies. It can help to identify new drug targets and treatment options for asthma. This can include the development of novel drugs, biologics, or combination therapies that may provide more effective and targeted treatment options for people with asthma.

Investment in R&D can help to improve the understanding of the underlying mechanisms of asthma and identify new biomarkers for diagnosis and monitoring. This can enable more personalized treatment approaches, which may lead to better outcomes and reduced healthcare costs. Investment in R&D can help to improve asthma management and education, leading to better self-management of the disease and reduced healthcare utilization. It can include the development of new devices and technologies for monitoring and managing asthma symptoms, as well as education programs for healthcare providers and patients.

Market Segmentation

Global asthma treatment market can be segmented by drug class, mode of administration, distribution channel, and region. Based on drug class, global asthma treatment market can be divided into short-acting beta-agonists (SABA), long-acting beta-agonists (LABA), inhaled corticosteroids (ICS), leukotriene modifiers, immunomodulators, combination drugs, and others. Based on mode of administration, the global asthma treatment market is divided into inhalers, nebulizers, and oral medications. Based on distribution channel, the global asthma treatment market is divided into hospital pharmacies, retail pharmacies, online pharmacies, and others. Regionally, the global asthma treatment market can be categorized into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

Market Players

GlaxoSmithKline, Plc., AstraZeneca Plc, Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim Gmbh, Merck & Co. Inc, Novartis AG, Sanofi SA, Roche Holding AG, Regeneron Pharmaceutical Inc, Pfizer Inc. are some of the leading players operating in the global asthma treatment market.

Report Scope:

In this report, global asthma treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Asthma Treatment Market, By Drug Type:

  • Short Acting Beta-Agonists (SABA)
  • Long-Acting Beta-Agonists (LABA)
  • Inhaled Corticosteroids (ICS)
  • Leukotriene Modifiers
  • Immunomodulator
  • Combination Drugs
  • Others

Asthma Treatment Market, By Mode of Administration:

  • Inhalers
  • Nebulizers
  • Oral Medications
  • Asthma treatment Market, By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Asthma Treatment Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Asia Pacific
  • India
  • Japan
  • South Korea
  • Australia
  • China
  • South America
  • Brazil
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in global asthma treatment market.

Available Customizations:

  • With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Asthma Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Short acting beta-agonists (SABA), Long-acting beta-agonists (LABA), Inhaled corticosteroids (ICS), Leukotriene modifiers, Immunomodulators, Combination drugs, Others)
    • 5.2.2. By Mode Of Administration (Inhalers, Nebulizers, Oral medications)
    • 5.2.3. By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2022)
  • 5.3. Product Map
    • 5.3.1. By Drug Class
    • 5.3.2. By Mode of Administration
    • 5.3.3. By Distribution Channel

6. North America Asthma Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Mode of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Asthma Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Mode of Administration
        • 6.3.1.2.3. Distribution Channel
    • 6.3.2. Canada Asthma Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Mode of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Asthma Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Mode of Administration
        • 6.3.3.2.3. By Distribution Channel

7. Europe Asthma Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Mode of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Asthma Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Mode of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Germany Asthma Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Mode of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Asthma Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Mode of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Asthma Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Mode of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Asthma Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Mode of Administration
        • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Asthma Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Mode of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. India Asthma Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Mode of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. Japan Asthma Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Mode of Administration
        • 8.3.2.2.3. By distribution Channel
    • 8.3.3. South Korea Asthma Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Mode of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. Australia Asthma Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Mode of Administration
        • 8.3.4.2.3. By Distribution Channel

9. South America Asthma Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Mode of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Asthma Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Mode of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Argentina Asthma Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Mode of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Colombia Asthma Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Mode of Administration
        • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Asthma Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Mode of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Asthma Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Mode of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Saudi Arabia Asthma Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Mode of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. UAE Asthma Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Mode of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Asthma Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Product Offerings
  • 15.3. Recent Developments
  • 15.4. Key Personnel
  • 15.5. SWOT Analysis
    • 15.5.1. GlaxoSmithKline, Plc.
    • 15.5.2. AstraZeneca Plc
    • 15.5.3. Teva Pharmaceutical Industries Ltd
    • 15.5.4. Boehringer Ingelheim Gmbh
    • 15.5.5. Merck & Co. Inc
    • 15.5.6. Novartis AG
    • 15.5.7. Sanofi SA
    • 15.5.8. Roche Holding AG
    • 15.5.9. Regeneron Pharmaceutical Inc
    • 15.5.10. Pfizer Inc.

16. Strategic Recommendations